Tuberculosis Therapeutics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Disease Type (Active TB, Latent TB), By Therapy (First-Line Therapy, Second-Line Therapy), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Tuberculosis Therapeutics Market is projected to grow from USD 2.27 Billion in 2025 to USD 3.14 Billion by 2031, achieving a Compound Annual Growth Rate of 5.56%. This market focuses on the commercialization and distribution of pharmacological agents, including first-line and second-line antibiotics, for treating active and latent Mycobacterium tuberculosis infections. It is primarily propelled by the persistent global burden of multi-drug resistant strains and sustained financial commitments from international health organizations aimed at disease eradication, which establish a foundational demand and ensure stable procurement, especially in high-burden regions dominated by government purchasing.
Market Driver
The market is significantly driven by the increasing prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB), which heightens the global demand for advanced second-line and combinatorial treatments as resistance to standard first-line antibiotics expands. For instance, the WHO reported 400,000 people developed MDR/RR-TB in 2023, compelling national health programs to acquire specialized regimens. Simultaneously, the introduction of shorter and more effective all-oral treatment regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), is transforming clinical protocols and boosting the adoption of innovative therapies. The shift from lengthy, injectable courses to streamlined oral regimens markedly improves patient adherence and clinical success rates, leading to rapid uptake by healthcare authorities, with the global MDR/RR-TB treatment success rate rising to 68%. This widespread deployment is supported by organizations like the Global Fund, which treated a record 7.1 million people for tuberculosis in 2023, indicating substantial therapeutic volume requirements.
Market Challenge
However, the market's expansion is significantly hindered by chronic underfunding, which restricts national health programs' capacity to procure and distribute essential antibiotic regimens, disrupting supply chains and diminishing incentives for pharmaceutical companies to invest in novel therapeutics. This financial deficit results in a stagnant product pipeline, particularly affecting high-burden regions where dependence on external donor funding leads to reliance on older medications, as only US$ 5.7 billion was available for TB services in 2024, far short of global requirements. This persistent gap consequently limits the addressable market and revenue prospects for therapeutic developers.
Market Trends
Despite these challenges, the market is witnessing transformative trends, including innovation in pediatric-friendly dispersible fixed-dose combinations that offer precise, palatable formulations, improving adherence and bioavailability for young patients—a demographic with a record 700,000 children notified with TB in 2023. Additionally, the integration of Artificial Intelligence in anti-tubercular drug discovery is revolutionizing the R&D pipeline, with generative models and machine learning algorithms being leveraged to efficiently identify novel chemical entities and drug targets, thereby accelerating early-stage discovery and enabling the development of new antibiotic classes capable of circumventing existing resistance mechanisms, as demonstrated by successful initiatives using generative AI to identify promising compounds.
Key Market Players
* AstraZeneca PLC
* Johnson & Johnson Services, Inc.
* Eli Lilly and Company
* Mylan Inc.
* Teva Pharmaceutical Industries Ltd
* Sanofi S.A.
* Novartis AG
* Sun Pharmaceutical Industries Ltd
* Pfizer Inc.
Report Scope
In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Tuberculosis Therapeutics Market, By Disease Type
* Active TB
* Latent TB
# Tuberculosis Therapeutics Market, By Therapy
* First-Line Therapy
* Second-Line Therapy
# Tuberculosis Therapeutics Market, By Route of Administration
* Oral
* Parenteral
* Others
# Tuberculosis Therapeutics Market, By Dosage Form
* Tablets
* Capsules
* Injection
* Others
# Tuberculosis Therapeutics Market, By Distribution Channel
* Hospital Pharmacy
* Retail Pharmacy
* Online Pharmacy
# Tuberculosis Therapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.
Available Customizations:
Global Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Tuberculosis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Active TB, Latent TB)
5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Tuberculosis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Therapy
6.2.3. By Route of Administration
6.2.4. By Dosage Form
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Tuberculosis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Therapy
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Dosage Form
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Tuberculosis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Therapy
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Dosage Form
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Therapy
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Dosage Form
6.3.3.2.5. By Distribution Channel
7. Europe Tuberculosis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Therapy
7.2.3. By Route of Administration
7.2.4. By Dosage Form
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Tuberculosis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Therapy
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Dosage Form
7.3.1.2.5. By Distribution Channel
7.3.2. France Tuberculosis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Therapy
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Dosage Form
7.3.2.2.5. By Distribution Channel
7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Therapy
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Dosage Form
7.3.3.2.5. By Distribution Channel
7.3.4. Italy Tuberculosis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Therapy
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Dosage Form
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Tuberculosis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Therapy
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Dosage Form
7.3.5.2.5. By Distribution Channel
8. Asia Pacific Tuberculosis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Therapy
8.2.3. By Route of Administration
8.2.4. By Dosage Form
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Tuberculosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Therapy
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Dosage Form
8.3.1.2.5. By Distribution Channel
8.3.2. India Tuberculosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Therapy
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Dosage Form
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Tuberculosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Therapy
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Dosage Form
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Therapy
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Dosage Form
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Tuberculosis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Therapy
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Dosage Form
8.3.5.2.5. By Distribution Channel
9. Middle East & Africa Tuberculosis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Therapy
9.2.3. By Route of Administration
9.2.4. By Dosage Form
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Tuberculosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Therapy
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Dosage Form
9.3.1.2.5. By Distribution Channel
9.3.2. UAE Tuberculosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Therapy
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Dosage Form
9.3.2.2.5. By Distribution Channel
9.3.3. South Africa Tuberculosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Therapy
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Dosage Form
9.3.3.2.5. By Distribution Channel
10. South America Tuberculosis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Therapy
10.2.3. By Route of Administration
10.2.4. By Dosage Form
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Tuberculosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Therapy
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Dosage Form
10.3.1.2.5. By Distribution Channel
10.3.2. Colombia Tuberculosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Therapy
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Dosage Form
10.3.2.2.5. By Distribution Channel
10.3.3. Argentina Tuberculosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Therapy
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Dosage Form
10.3.3.2.5. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Tuberculosis Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AstraZeneca PLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Johnson & Johnson Services, Inc.
15.3. Eli Lilly and Company
15.4. Mylan Inc.
15.5. Teva Pharmaceutical Industries Ltd
15.6. Sanofi S.A.
15.7. Novartis AG
15.8. Sun Pharmaceutical Industries Ltd
15.9. Pfizer Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們